Synairgen rockets 450% on positive Covid-19 trial news! Is now time to buy?

Synairgen shareholders are popping corks today as the share price soars. Are positive Covid-19 trial results reason enough to buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Synairgen (LSE:SNG) early investors have made a fortune today after the Covid-19 testing firm reported breakthrough trial results.

The AIM-listed biotech reported positive results from an early trial of its SNG001 drug.

Synairgen said its respiratory coronavirus treatment produced a 79% lower risk of patients developing severe disease compared to those given a placebo.

Patients who received the inhaled interferon beta drug were “more than twice as likely to recover over the course of the treatment”, the UK company said.

Shares soared over 5oo% in the early hours of trading on Monday, before settling closer to 450% towards the end of the day.

But even with this huge jump, I think Synairgen could go higher.

Buy Synairgen now?

Covid-19 testing firms have been in a pharma arms race since the novel coronavirus first hit our shores.

Those with the best prospects have been propelled to epic new heights.

And there are investors on both sides of the Atlantic keen to profit from buying the winners from Covid-19 testing. So I think there are a multitude of buyers who will support the Synairgen share price at current levels and higher.

This has been backed up by City analysts. Broker finnCap tripled its price target from 120p to 360p on the back of the breakthrough news. That target is 110% higher than the Synairgen share price now.

And all the positive press from the likes of Sky News, BBC, and even CNBC in the US is good for the Synairgen share price.

Caveats

I will put forward a few reasons not to buy Synairgen, for the sake of balance.

This could be a case of ‘buy the rumour, sell the news’. Small, unprofitable, as-yet-unproven companies tend to attract speculators happy to take on massive risk. Their rewards could be spectacular. But if Synairgen can’t bring a product to market quickly, the share price could deflate just as fast as it soared.

I’m also not convinced Synairgen is a share I’d buy and hold for 20 years. This is AIM, after all. Financial reporting requirements are less stringent than on the main market. It is definitely more of a punt than sticking to quality, high-value FTSE 100 shares.

Less than a year ago Synairgen was trading at 6p. Its fair value could be as low as 40p. This is an equation based on earnings per share, annual earnings growth, and return on capital.

There is still a big ‘if’ attached to Synairgen. If hope and hype wanes, the share price will likely trend back towards its fair value.

Buy or sell Synairgen?

When I last covered Synairgen back in April, its market cap was just £75 million — right at the bottom of the range I’d be happy investing in.

With this news of a potential Covid-19 trial breakthrough, the company’s market cap has hit £260 million.

And volume has soared as the market digests the news. 22 million shares had changed hands before noon on Monday 20 July.

So with more liquidity available (more people buying and selling) there is a better chance for investors buying now to get in and out of positions at the price they want.

It’s okay to let others take on all the early risk by investing in unproven companies. I’d still say Synairgen is worth a short-term punt, but don’t put your life savings on the line.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Tom Rodgers has no position in the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Under £14 now, Persimmon’s share price is trading at less than half its fair value by my reckoning

Persimmon’s share price fell a lot over the past year, but I think a new home-building initiative and improved macroeconomic…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Is this FTSE 100 pharma gem now a brilliant bargain?

This FTSE 100 pharmaceutical giant has been hit by fears of US tariffs and litigation over a key product, but…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Is Warren Buffett losing his touch?

Our writer's noticed that Warren Buffett’s investment vehicle has underperformed the S&P 500 during three of the past four years.…

Read more »

Investing Articles

Non-energy minerals are the top performers in 2025. These small-cap FTSE shares are leading the charge

Mark Hartley examines which sectors are doing well in 2025 and the FTSE shares that investors should consider to benefit…

Read more »

Emma Raducanu for Vodafone billboard animation at Piccadilly Circus, London
Investing Articles

Buying 10,000 Vodafone shares generates a passive income of…

Vodafone shares have had a rough ride, with dividends slashed in half. But with its turnaround making steady progress, is…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Buying 1,000 Aviva shares generates an income of…

Aviva shares could be primed to thrive in the long run if its takeover of Direct Line is a success,…

Read more »

Investing Articles

At today’s price, buying 1,000 British American Tobacco shares generates a second income of…

Tobacco companies may not be popular, but the British American Tobacco share price is on the rise, along with its…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

The cheapest UK stock in my ISA is…

This UK stock currently trades at a massive discount to the market. Edward Sheldon believes it's mispriced and that there's…

Read more »